NVO Stock Price and Chart — NYSE:NVO

Overview

Financials News Ideas Discussions Technicals Forecast Seasonals Options Bonds

Key facts today

Novo Nordisk's Wegovy, a weight-loss drug, launched in India in June. Biocon aims to release generics in India and Canada by 2026, aligning with semaglutide's patent expiration.

Berenberg holds a 'hold' rating for Novo Nordisk (NOVO_B) as investors await US prescription data for Wegovy, vital for evaluating the drug's growth, with a price target of 610 DKK.

Novo Nordisk ended its partnership with Hims & Hers Health on June 23, 2025, due to U.S. regulatory violations and deceptive marketing, resulting in class action lawsuits against Hims & Hers.

Analyze the impact Analyze the impact

About NOVO NORDISK B A/S

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Check out other big names from the same industry as NVO.